Рисперидон при лечении психотических и поведенческих симптомов деменции

1. Колыхалов И.В., Селезнева Н.Д., Калын Я.Б., Гаврилова С.И. Рисполепт в терапии некогнитивных симптомов болезни Альцгеймера. Псих. и психофармакотер. 2002; 6: 226–9.
2. Ballard C, Saad K, Patel A et al. The prevalence and phenomenology of psychotic symptoms in dementia sufferers. Int J Geriatr Psychiat 1995; 10: 477–85.
3. Barnes R, Veith R, Okimoto J et al. Efficacy of antipsychotic medication in behaviourally disturbed dementia patients. Am J Psychiat 1982; 139: 1170–4.
4. Bhana N, Spenser CM. Risperidone: A review of its use in the management of the behavioural and psychological symptoms of dementia. Drugs Aging 2000; 16: 450–71.
5. Burns A, Jacoby R, Levy R. Psychiatric phenomena in Alzheimer's disease. Br J Psychiat 1990; 157: 72–94.
6. Chen P, Ganguli M, Mulsant BH et al. The temporal relationship between depressive symptoms and dementia. Arch Gen Psychiat 1999; 56: 261–6.
7. Cooper JK, Mingas D, Verma M et al. Psychotic symptoms in Alzheimer's disease. Int J Geriatr Psychiat 1991; 6: 721–6.
8. Craig AH, Cummings JL, Fairbanks L et al. Cerebral blood flow correlates of apathy in Alzheimer disease. Arch Neurol 1996; 53: 1116–20.
9. Cummings JL. Cholinesterase inhibitors: Anew class of psychotropic compounds. Am J Psychiat 2000; 157: 4–15.
10. De Smedt G, Lemmens P, Wyffels V et al. Clinical expert report of risperidone in the treatment behavioural disturbances in patients with dementia. Beerse: Janssen Research Foundation; 1997. Clin Trial Report. R-64766.
11. DeDeyn PP, Katz IR. Control of aggression in patients with dementia: efficacy and safety of risperidon. Int J Geriatr Psychiat 2000; 15: 14–22.
12. DeDeyn PP, Rabheru K, Rasmussen A et al. A randomized trial of risperidone, placebo and haloperidol for behavioural symptoms of dementia. Neurology 1999; 53: 946–55.
13. Ereshefsky L, Lacombe S. Pharmacological profile of risperidone. Can J Psychiat 1993; 38 (Suppl. 3): 80–8.
14. Ferris SH, Steinberg G, Shulman E et al. Institutionalization of Alzheimer's disease patients: reducing precipitating factors through family counselling. Home Health Care Services Quarterly. 1987; 8: 23–51.
15. Finkel S. Introduction to behavioural and psychological symptoms of dementia (BPSD). Int J Geriatr Psychiat 2000; 15: 2–4.
16. Finkel SI. The significance of the behavioural and psychological symptoms of dementia. Clinician 1998; 16: 33–42.
17. Goldberg RJ, Goldberg J. Risperidone for dementia-related disturbed behaviour in nursing home residents: a clinical experience. Int Psychogeriatr 1997; 9: 65–8.
18. Gottfries CG. Depression and Alzheimer's disease. In: Robert E, Becker E, Ezio Giacobini E et al. (eds.). Alzheimer Disease: From Molecular Biology to Therapy. Boston, 1997; 495–9.
19. Gottlieb GL, McAllister TW, Gur RC. Depot neuroleptics in the treatment of behavioural disorders in patients with Alzheimer's disease. J Am Geriatr Soc 1988; 36: 619–21.
20. Hirano N, Mega MS, Dinov ID et al. Left fronto-temporal hypoperfusion is associated with aggression in patients with dementia. Arch Neurol 1988; 23: 616–20.
21. Irizarry MC, Ghaemi SN, Lee-Cherry ER et al. Risperidone treatment of behavioral disturbances in outpatients with dementia. J Neuropsych Clin Neurosci 1999; 11 (3): 336–42.
22. Katz IR, Jeste DV, Mintzer JE. Comparison of risperidone and placebo for psychosisand behavioral disturbances associated with dementia: a randomized double-blind trial. J Clin Psychiat 1999; 60: 107–15.
23. Kelly DL, Conley RR, Love RC et al. Weight gain in adolescents treated with risperidone and conventional antipsychotics over six months. J Child Adolesc Psychopharmacol 1998; 8: 151–9.
24. Lemmens P, Brecher M, Van-Baelen B. A combined analysis of double-blind studies with risperidone vs. placebo and other antipsycholic agents: factors associated with extrapyramidal symptoms. Acta Psychiair Scand 1999; 99: 160–70.
25. Lyketsos CG, Steele C, Baker L et al. Major and minor depression in Alzheimer's disease:Prevalence and impact. J Neuropsychiatry Clin Neurosci 1997; 9: 556–61.
26. Mega MS, Materman DM, O'Connor S et al. The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer disease. Arch Neurol 1999; 56: 1388–93.
27. O'Donnell BF, Drachman DA, Barnes HJ et al. Incontinence and troublesome behaviours predict institutionalization in dementia. Geriatr Psychiat Neurol 1992; 5: 45–52.
28. Petrie WM, Ban ТА, Berney S et al. Loxapine in psychogeriatrics: A placebo- and standard-controlled clinical investigation. J. Clin. Psychophamacol 1982; 2: 122–6.
29. Pickar D. Prospects for pharmacotherapy of schizophrenia. Lancet 1995; 345: 557–61.
30. Ray WA, Griffin MR, Schaffner W et al. Psychotropic drug use and the risk of hip fracture. N Engi J Med 1987; 316: 363–9.
31. Risse SC, Lampe TH, Cubberley L. Very low-dose neuroleptic treatment in two patients with agitation associated with Alzheimer's disease. J Clin Psych 1987; 48: 208.
32. Salzman C. Treatment of the agitated demented elderly patient. Hosp Commun Psych 1988; 39 (Suppl.): 1143–4.
33. Sweet RA, Pollock BG. New atypical antipsychotics: experience and utility in the elderly. Drugs Aging 1998; 12 (2): 115–27.
34. Tariot PN, Blazina L. The psychopathology of dementia. In: Morris JC, editor. Handbook of dementing illnesses. New York: Marcel Dekker lnc., 1994; 461–75.
35. Tariot PN, Mack JL, Patterson MB et al. The behavior rating scale for dementia of the consortium to estab ish a registry for Alzheimer's Disease. Am J Psychiat 1995; 152: 1349–57.
36. Tractenberg RE, Weiner MF, Thal LJ. Estimating the prevalence of agitation of community-dwelling persons with Alzheimer's disease. J Neuropsych Clin Neurosci 2002; 14: 11–8.
37. Zarate JrCA, Baldessarini RJ, Siegel AJ et al. Risperidone in the elderly: a pharmacoepidemiologic study. J Clin Psych 1997; 58: 311–7.